We are conducting multiple observational clinical trials. The primary objective of these trials is to determine the ex vivo predictive accuracy of elive™ across a variety of solid tumors. Learn more about our current and completed trials below.
Study endpoints:
Measured per RECIST v1.1 and iRECIST
Mayo Clinic MC230901: Observational Basket Trial to Collect Tissue to Develop and Train and Validate a Live Tumor Diagnostic Platform
Tumor types: Bladder cancer, Colorectal cancer, Endometrial cancer, Head & neck cancer, Kidney cancer, Liver cancer, Melanoma, Non-small cell lung cancer, Triple negative breast cancer, Esophageal cancer, Cervical cancer
Observational Trial to Collect Tumor Tissue and Clinical Data From Patients Undergoing Biopsy for Suspected or Confirmed Cancer to Characterize Ex Vivo Response to Immunotherapy
Tumor types: Bladder cancer, Triple negative breast cancer, Colorectal cancer, Endometrial cancer, Head & neck cancer, Kidney cancer, Liver cancer, Non-small cell lung cancer, Melanoma
These trials will provide an opportunity to demonstrate correlation between ex vivo and clinical response to immunotherapy regimens.
Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform
Tumor types: Non-small cell lung cancer
Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform
Tumor types: Bladder cancer, Colorectal cancer, Endometrial cancer, Head & neck cancer, Kidney cancer, Liver cancer, Melanoma, Non-small cell lung cancer
Hospitals and academic research centers within the US provide consented patient specimens.
If you are a physician or researcher, contact us to learn more.